Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 1.00 |
| ▸ | JAK1 | P23458 | 17/20 | 1.00 |
| ▸ | JAK3 | P52333 | 14/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.68 |
| ▸ | ULK1 | O75385 | 1/20 | 0.68 |
| ▸ | PRKCB | P05771 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | PRKCA | P17252 | 1/20 | 0.68 |
| ▸ | PRKACA | P17612 | 1/20 | 0.68 |
| ▸ | MARK3 | P27448 | 1/20 | 0.68 |
| ▸ | TYK2 | P29597 | 1/20 | 0.68 |
| ▸ | STAT3 | P40763 | 1/20 | 0.68 |
| ▸ | CLK1 | P49759 | 1/20 | 0.68 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.68 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.68 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.68 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.68 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100359 | 0.91 | JAK2 (0.83) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL100609 | 0.91 | JAK2 (0.83) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL29541207 | 0.91 | JAK2 (0.83) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL99411 | 0.90 | JAK2 (0.82) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL871842 | 0.89 | JAK2 (0.80) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL102406 | 0.87 | JAK2 (0.77) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL15392917 | 0.86 | JAK2 (0.75) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL18269204 | 0.85 | JAK2 (0.78) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL2605490 | 0.85 | JAK2 (0.74) | JAK2JAK1JAK3CITGAK | |
| SCHEMBL19831998 | 0.85 | JAK2 (0.75) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790158-B | Heterocyclic compounds as JAK inhibitors, salts of the compounds and therapeutic use thereof | 苏州隆博泰药业有限公司 | 2022-06-24 | — | — | CN | claimed |
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | claimed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | claimed |
| US-11414413-B2 | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof | SUZHOU LONGBIOTECH PHARMACEUTICALS CO., LTD. (CN) | 2022-08-16 | — | — | US | disclosed |
| CN-109790158-B | Heterocyclic compounds as JAK inhibitors, salts of the compounds and therapeutic use thereof | 苏州隆博泰药业有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-3492468-B1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2022-02-23 | — | — | EP | disclosed |
| EP-3492468-B1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | SUZHOU LONGBIOTECH PHARMACEUTICALS CO LTD (CN) | 2022-02-23 | — | — | EP | disclosed |
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | TIANJIN LONGBOGENE PHARMACEUTICAL CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| EP-3492468-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | Tianjin Longbogene Pharmaceutical Co., Ltd. (CN) | 2019-06-05 | — | — | EP | disclosed |
| WO-2018019222-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | 张文燕 | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270740-A1 | HETEROCYCLIC COMPOUND AS JAK INHIBITOR, AND SALTS AND THERAPEUTIC USE THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
| US-11414413-B2 | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.